tm logo
DUVROQ
REGISTERED

on 25 Jun 2019

Last Applicant/ Owned by

GLAXO GROUP LIMITED

GSK Medicines Research CentreGunnels Wood RoadStevenage, SG1 2NY

GB

Serial Number

1926989 filed on 24th Oct 2018

Registration Number

TMA1031300 registered on 25th Jun 2019

Registration expiry Date

25th Jun 2029

Correspondent Address

World Exchange Plaza100 Queen Street, Suite 1300Ottawa

ONTARIO

CA

K1P1J9

DUVROQ

Trademark usage description

pharmaceutical preparations for use as anti-infectives; pharmaceutical preparations for the treatment of viral conditions, namely human immunodeficien Read More

Classification Information


Class [005]
Pharmaceutical preparations for use as anti-infectives; pharmaceutical preparations for the treatment of viral conditions, namely human immunodeficiency virus (HIV), human papilloma virus, respiratory syncytial virus, hepatitis, herpes genitalis, herpes labialis, herpes simplex virus, varicella-zoster virus, Epstein-Barr virus and cytomegalovirus; pharmaceutical preparations for the treatment and prevention of respiratory diseases and disorders and their symptoms; pharmaceutical preparations for the treatment of immune system related diseases and disorders, namely immunosuppressants; pharmaceutical preparations for the treatment of immunologic diseases and disorders namely, autoimmune diseases and disorders; pharmaceutical preparations for the treatment of atherosclerosis; pharmaceutical preparations for the treatment of viral conditions namely human immunodeficiency virus (HIV), HPV, RSV, hepatitis, herpes genitalis, herpes labialis, herpes simplex virus, varicella-zoster virus, Epstein-Barr virus and cytomegalovirus; pharmaceutical preparations for the treatment and prevention of metabolic related diseases and disorders namely disorders of the endocrine system, namely growth and thyroid disorders, diabetes, metabolic syndrome, obesity, weight loss and weight management; pharmaceutical preparations for the treatment and prevention of cardiovascular, cardiopulmonary, cardio-renal and renal diseases and disorders; pharmaceutical preparations for the prevention and treatment of oncological diseases and disorders; pharmaceutical preparations for the treatment of inflammation and inflammatory related diseases and disorders namely arthritis, rheumatoid arthritis, inflammatory bowel diseases, inflammatory connective tissue diseases, vasculitis, synovitis; pharmaceutical preparations for the prevention and treatment of sequelae of oncologic diseases and their treatment namely nausea and vomiting, hematologic depression, mucositis, cachexia, pain, bone pain and fatigue; pharmaceutical preparations for the treatment of blood-related diseases and disorders namely thrombocytopenia, coagulation disorders, bleeding disorders, platelet disorders, blood vessel disorders, sickle-cell disease and its related disorders, anemias, sepsis and infections in and of the blood; pharmaceutical preparations for the treatment of musculoskeletal diseases, disorders and injuries namely connective tissue diseases, bone diseases, osteoporosis, spinal diseases, back pain, gout, fractures, sprains, sports injuries, osteogenesis imperfecta, muscle wasting (cachexia), renal osteodystrophy, cartilage injuries, joint replacement and osteoarthritis; pharmaceutical preparations for use in ophthalmology; pharmaceutical preparations for the treatment of dermatological diseases and disorders namely dermatitis, skin and skin structure infections namely bacterial skin infections, fungal skin infections, viral skin infections and parasitic skin infections, psoriasis, eczema and sexually transmitted diseases; pharmaceutical preparations for the treatment of hormonal related diseases and disorders namely hypogonadism, testosterone/androgen disorders and estrogen disorders; pharmaceutical preparations for the treatment of gastrointestinal related diseases and disorders namely irritable bowel disorders and symptoms, digestive disorders and acid-related disorders; pharmaceutical preparations for the treatment of sexual dysfunction namely erectile dysfunction, male and female sexual dysfunction disorders namely arousal disorder, pain disorder, desire disorder and orgasm disorder; pharmaceutical preparations for the treatment of genitourinary diseases namely urological diseases and disorders; pharmaceutical preparations for the treatment of gynaecological diseases and disorders namely amenorrhoea, dysmenorrheal and infertility; pharmaceutical hormonal preparations namely corticosteroids, hormone replacement therapy preparations, oral contraceptives, thyroid hormone preparations; pharmaceutical preparations for the treatment of incontinence, prostate diseases and disorders, bladder diseases and disorders; pharmaceutical preparations for the treatment of sexually transmitted diseases, inflammatory pelvic diseases, vasomotor/menopausal symptoms, endometriosis/uterine fibroids, Leiomyoma, endourology/stone, pre-eclampsia and pre-term labour; pharmaceutical preparations for the treatment of prostatitis, nephritis, cystitis, vaginitis, renal disease; pharmaceutical preparations for the treatment of premenstrual dysphoric disorder, premenstrual syndrome, male hypogonadism and hormonal disorders namely polycystic ovary syndrome; pharmaceutical preparations for the treatment of hepatological related diseases namely hepatitis, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), liver fibroids, and cirrhosis; pharmaceutical preparations for the treatment of alopecia and androgenic alopecia (male pattern baldness); pharmaceutical preparations for the treatment of psychiatric diseases and disorders namely mood disorders, anxiety disorders, cognitive disorders, schizophrenia, and psychoses; pharmaceutical preparations for the treatment of damaged skin and tissue namely bee stings, sunburn, rashes, sores, corns, calluses and acne; pharmaceutical preparations for the treatment of inflammatory connective tissue diseases and injuries; pharmaceutical preparations for the treatment of malaria; pharmaceutical preparations for the treatment of tuberculosis; Allergy medications; Vaccines namely prophylactic and therapeutic vaccines for humans; pharmaceutical preparations for the treatment of neurological diseases and disorders namely Parkinsons Disease, Alzheimers Disease, Huntingtons Disease, dementia, migraine, cerebral palsy, brain injury, spinal cord injury, seizure disorders, epilepsy, restless legs syndrome, pain, neuropathic pain, inflammatory-related pain, fibromyalgia, stroke, multiple sclerosis, insomnia; pharmaceutical preparations for the treatment of central nervous system diseases and disorders namely central nervous system infections, brain diseases, central nervous system movement disorders, ocular motility disorders, spinal cord diseases, depression and anxiety and their related disorders namely schizophrenia and psychoses; pharmaceutical preparations for the treatment of muscular dystrophy


Classification kind code

11

Class [044]
Cell and gene therapy services


Classification kind code

11

Mark Details


Serial Number

1926989

Mark Type

Trademark

Legal History


Show more

Action TakenStatus
Submitted for opposition 55
on 25th Jun 2019
Registered
Submitted for opposition 190
on 20th Jun 2019
Registration Pending
Submitted for opposition 191
on 20th Jun 2019
Registration Fee Notice Sent
Submitted for opposition 42
on 06th Mar 2019
Advertised
Submitted for opposition 26
on 28th Feb 2019
Approved
Submitted for opposition 22
on 10th Jan 2019
Search Recorded
Submitted for opposition 27
on 10th Jan 2019
Approval Notice Sent
Submitted for opposition 31
on 29th Oct 2018
Formalized
Submitted for opposition 1
on 25th Oct 2018
Created
Submitted for opposition 30
on 24th Oct 2018
Filed